CSNK2B and non-small cell lung carcinoma: In this study, it is aimed to explore the potential of targeting CK2 and its regulatory subunit CK2B to prevent or reverse T‐cell exhaustion, thereby enhancing the efficacy of anti‐PD‐1 therapy in NSCLC.